Ohio’s decision not to cover the cost of GLP-1 obesity medications like Ozempic and Wegovy through its state employee health plan has drawn sharp criticism from healthcare advocates who argue the policy is both shortsighted and fiscally irresponsible. An opinion piece in The Columbus Dispatch highlights how the state’s refusal to provide coverage for these proven weight-loss medications contradicts the growing body of evidence demonstrating their long-term health and economic benefits.
The controversy centers on medications originally developed for type 2 diabetes that have shown remarkable effectiveness in treating obesity. Clinical trials have demonstrated that semaglutide, the active ingredient in Ozempic and Wegovy, can help patients achieve weight loss of 15% or more of their body weight. These results have prompted medical societies to increasingly recognize obesity as a chronic disease requiring pharmaceutical intervention, not simply lifestyle changes.
Critics of Ohio’s policy argue that refusing coverage for obesity medications will ultimately cost the state more money in the long run. Obesity is a primary risk factor for numerous expensive chronic conditions including type 2 diabetes, heart disease, stroke, and certain cancers. By preventing or delaying these conditions through weight management, the medications could reduce healthcare expenditures significantly over time. Research suggests that for every dollar spent on obesity treatment, states can save several dollars in future healthcare costs.
The debate reflects a broader tension playing out across the country as insurers and government health plans grapple with the high list prices of GLP-1 medications, which can exceed $1,000 per month. Many health plans have implemented strict coverage limitations or excluded the drugs entirely for weight management purposes, even while covering them for diabetes treatment.
For Ohio state employees struggling with obesity, the lack of coverage means paying out-of-pocket costs that are prohibitive for most families. Healthcare advocates argue this creates a two-tiered system where only wealthy individuals can access effective obesity treatment, potentially widening existing health disparities.
